News

Health care environmental professionals met in Dallas, Texas, from July 31 to August 2, 2023, at the AHE Exchange Conference & Solution Center. Infection Control Today® asked Rock Jensen, AHE advisory board chair and administrative director of support services for Yuma Regional Medical Center in Arizona, about AHE’s areas of emphasis for leadership in environmental services (EVS).

Besides its influenza pipeline, mRNA technology is helping this pharmaceutical company create a number of new vaccines for cancer, rare diseases, and infectious diseases.

Hepatitis C cases increased in 2021, while A and B decreased. The pandemic may have impacted the progress.

A recent survey aimed to understand Americans' concerns and knowledge about hospitalization. Infection Control Today speaks to 2 of the authors.

A recent conference highlights patient safety in health care and aims to reduce risks and harm to patients during medical care. It's a response to the growing complexity of health care systems and the resulting increase in patient harm.

All eye drops from Dr. Berne’s Whole Health Products are being recalled after FDA warning on August 24. There are 2 adverse reactions reported so far.

This guide aims to assist hospitals in identifying and managing sepsis at an earlier stage. ICT interviews 1 of the authors.

Eagle Pharmaceuticals randomized its first patient in the Phase 2 study of CAL02, a safe and promising anti-toxin drug that treats severe community-acquired bacterial pneumonia without contributing to antibiotic resistance.

Take 5 minutes to catch up on Infection Control Today®’s highlights for the week ending Aug 20, 2023.

Connecting and networking with colleagues, finding the right resources, and joining key organizations can help you become a better infection preventionist.

Visible-light continuous environmental disinfection system reduces microbial contamination and surgical site infections, as noted in an AJIC study. Experts explain the study and the technology.

Take 5 minutes to catch up on Infection Control Today®’s highlights for the week ending July 30, 2023.

A new remote sexual health testing provider is available to US public health officials. It aims to reduce the increasing spread of sexually transmitted infections.

In this opinion article, the authors discuss their concerns about the recent HICPAC/CDC proposals on infectious diseases.

Neal Buchalter, MBA, president of Parker Laboratories, spoke with Infection Control Today® in an exclusive interview about the product, the companies involved, and how it came to the US market.

AstraZeneca's new drug, a monoclonal antibody, was given FDA approval after the Antimicrobial Drugs Advisory Committee (AMDAC) to the FDA voted in June to recommend the approval of nirsevimab (Beyfortus) for the prevention of respiratory syncytial virus (RSV) disease in infants.

As an oversight agency for the Department of Health and Human Services, the Office of Inspector General is responsible for ensuring the safety and effectiveness of Medicare and Medicaid programs, with a huge priority being patient care. These toolkits provide additional guidance on how to avoid patient injury.

In his analysis, Kevin Kavanagh, MD, explores the measures taken by the infectious disease sector in response to the pandemic, pointing out both effective and ineffective approaches. He also discusses how the pandemic has affected the treatment of other infectious diseases.

A small study explored the connection between Postural Orthostatic Tachycardia Syndrome (POTS) and the COVID-19 condition.

A session held at the APIC 2023 Annual Conference & Exhibition delved into the importance of equity in infection prevention and explored the impact of health inequities on the transmission of diseases.

Investigators studied 2 infants experiencing seizures, small head size, and developmental delays born of mothers who had contracted COVID-19 during pregnancy.

Legionnaires’ disease is a severe infection and fatal in 10% of cases.

Establishing a permanent system for monitoring the persistence and emergence of dangerous pathogens is necessary, especially COVID-19.

The vaccine is approved for use in adults aged 60 and older to prevent lower respiratory tract disease caused by RSV.

Saskia v. Popescu, PhD, MPH, MA, CIC, gives the latest on COVID-19, Marburg Virus Disease, and a 1-hit STI antibiotic plan.

Take 5 minutes to catch up on Infection Control Today®’s highlights for the week ending April 23, 2023.

Sulbactam-durlobactam is under priority review (PDUFA; May 29, 2023). 

Take 5 minutes to catch up on Infection Control Today®’s highlights for the week ending April 2, 2023.